beta(1)- and beta(2)-adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non-failing adult human heart.
about
G-protein Coupled Receptor Signaling in Pluripotent Stem Cell-derived Cardiovascular Cells: Implications for Disease ModelingInnate immunity in human embryonic stem cells: comparison with adult human endothelial cellsMaturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissuesIsoflurane preconditioning elicits competent endogenous mechanisms of protection from oxidative stress in cardiomyocytes derived from human embryonic stem cellsEmbryonic stem cell application in drug discovery.Refinement, reduction and replacement approaches to in vivo cardiovascular research.Present state and future perspectives of using pluripotent stem cells in toxicology researchModulation of human embryonic stem cell-derived cardiomyocyte growth: a testbed for studying human cardiac hypertrophy?Pathogen sensing pathways in human embryonic stem cell derived-endothelial cells: role of NOD1 receptors.Signaling via PI3K/FOXO1A pathway modulates formation and survival of human embryonic stem cell-derived endothelial cells.Embryonic stem cell-derived cardiomyocytes as a model to study fetal arrhythmia related to maternal diseaseIntegrated Analysis of Contractile Kinetics, Force Generation, and Electrical Activity in Single Human Stem Cell-Derived CardiomyocytesElectrophysiological and contractile function of cardiomyocytes derived from human embryonic stem cells.Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review.Embryonic stem cells for severe heart failure: why and how?Embryonic template-based generation and purification of pluripotent stem cell-derived cardiomyocytes for heart repair.The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening.Current status of drug screening and disease modelling in human pluripotent stem cells.Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes.Developmental cues for the maturation of metabolic, electrophysiological and calcium handling properties of human pluripotent stem cell-derived cardiomyocytes.Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes.Assessment of cellular toxicity of TiO2 nanoparticles for cardiac tissue engineering applications.Cardiac differentiation of pluripotent stem cells.Deciphering the beta-adrenergic response in human embryonic stem cell-derived-cardiac myocytes: closer to clinical use?IGF1 and NRG1 Enhance Proliferation, Metabolic Maturity, and the Force-Frequency Response in hESC-Derived Engineered Cardiac Tissues.GPCR theme editorial.Gene Transfer in Cardiomyocytes Derived from ES and iPS Cells.Human-Induced Pluripotent Stem Cell Technology and Cardiomyocyte Generation: Progress and Clinical Applications.Changing Metabolism in Differentiating Cardiac Progenitor Cells-Can Stem Cells Become Metabolically Flexible Cardiomyocytes?
P2860
Q26772221-C67AB22F-9C6D-4FE7-A40E-059D2163AFA6Q27329616-AC7FC390-CE2F-4BF6-ACF9-185436582E3EQ28550738-A25E10CB-6635-4832-8BC3-548819DA00AEQ30496731-48D0C115-42F1-48BE-BFC9-9B7774382AE6Q33565675-5E7BC4F4-338C-4868-AD38-1943487EA052Q34356067-7AA82BA9-3D0F-4E3D-A17D-DAE4C1D09599Q34520935-42F5B135-61B1-491E-8D24-372D48236BD1Q34557006-31A40582-F388-4F83-BEA3-F45D2CE67282Q35137398-4DF20A24-C207-47F1-B425-32A131780F67Q35200248-1B7703CB-B806-4C3E-89C9-E067B7026593Q35893377-D8AF55BB-3C76-4199-98E9-325BE6D49017Q36379865-19C57FC9-4984-4AB1-ADB0-DD0E0BE7F36EQ37542604-30924ED6-96DC-47AC-978A-788BA766EF32Q37844011-F99A35AE-080A-4DA3-A585-3DEFBFEEA9F6Q37992937-4E1E3457-0FBA-4531-AE7C-8AC46FE0797EQ38027106-9710EA5D-ABA6-4F63-BF08-A4E3724EE87AQ38030589-159B12A0-9189-4D16-93D9-84E9D4BD3206Q38034129-14D4E747-8295-432D-876C-E8C01FCEFE6EQ38077159-9BC918BA-73B2-46B2-B254-D702A61862B5Q38182186-1780407D-68B8-4AAC-9C91-EB8864E1D6D0Q39345477-9C4E1C78-7BA5-43CD-9B8B-1E36B13BC6C1Q39653193-59568AF7-E88D-4ED2-9223-9A26770B2803Q39747622-A7EBAB08-8AF6-4D9F-914B-7FF44CF2E29AQ40025464-1F9C6F08-3EA7-4090-B87F-2B85ED924A0DQ41690530-C09F8B5A-5BD2-46B9-AFC1-E43089AF1544Q42951309-87083C6C-B676-41A7-BF42-A5BEF0DC84D4Q45862441-4738199C-5B18-44CE-B8EF-CD91A3E4F69BQ55499094-6EFBAD1E-C148-416A-A9FC-E5C944FAEE46Q57072502-B1B84FD7-DB39-4C43-B9CF-F2D73323309B
P2860
beta(1)- and beta(2)-adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non-failing adult human heart.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
beta(1)- and beta(2)-adrenocep ...... non-failing adult human heart.
@ast
beta(1)- and beta(2)-adrenocep ...... non-failing adult human heart.
@en
type
label
beta(1)- and beta(2)-adrenocep ...... non-failing adult human heart.
@ast
beta(1)- and beta(2)-adrenocep ...... non-failing adult human heart.
@en
prefLabel
beta(1)- and beta(2)-adrenocep ...... non-failing adult human heart.
@ast
beta(1)- and beta(2)-adrenocep ...... non-failing adult human heart.
@en
P2093
P2860
P356
P1476
beta(1)- and beta(2)-adrenocep ...... non-failing adult human heart.
@en
P2093
M Brito-Martins
S E Harding
P2860
P304
P356
10.1038/SJ.BJP.0707619
P407
P577
2008-01-14T00:00:00Z